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Abstract 
Amphiregulin (AR), a heparin-binding, epidermal growth factor (EGF) receptor ligand has homology with EGF but exhibits a lower 
affinity for the EGF receptor than EGF. As the mature form of AR is truncated at the C terminus and lacks a conserved leucine residue 
known to be essential for high affinity binding of EGF to the EGF receptor, wild-type AR (AR1.84) , a C-terminally extended AR 
construct incorporating six residues from the predicted coding sequence of AR (mRl_90) and a similarly extended construct with a Met 86 
to Leu substitution (ARl_90(leu86)) were expressed as recombinant proteins in yeast, purified by heparin affinity and Cls reverse phase 
chromatography and their relative biological activities determined. The growth factors were tested in mitogenesis and EGF receptor 
autophosphorylation assays and their relative order of potencies was found to be leu s6 > met s6 > wt. The ARl_900e,s6) construct was 
found to be 50- to 100-fold more active than wild type ARl_84 consistent with previously reported studies of the role of the equivalent 
C-terminal leucine in EGF or TGFa. Significantly, the C-terminally extended form of AR, AR1.90 , which utilized six residues from the 
predicted coding sequence, was 10-times more active than wild type AR1.84. This difference in activity of the C-terminally extended form 
of AR may be of biological significance since differential proteolytic processing of the AR precursor in vivo could result in production of 
multiple forms of the growth factor with differing affinities for the EGF receptor and hence differing biological potencies. 
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1. Introduction 
The EGF receptor ligand family is widely involved in 
the control of cell growth and differentiation [1]. It com- 
prises a number of grov~:h factors which show sequence 
and structural homology 112] and includes EGF [3], trans- 
forming growth factor alpha (TGFa) [4], amphiregulin 
(AR) [5], heparin-binding EGF (HB-EGF) [6] and betacel- 
Abbreviations: AR, amphireguiin; EGF, human epidermal growth 
factor; TGFa, transforming growth factor-alpha; TGF/3, transforming 
growth factor-beta; wt, wild-type; HSPG, beparan sulfate proteoglycan; 
FPLC, fast protein liquid chromatography; TFA, trifluoracetic a id; ECL, 
enhanced chemiluminescence; DMEM, Dulbecco's modification of Ea- 
gle's medium; FBS, foetal bovine serum; PMSF, phenylmethylsulfonyl- 
fluoride; 125I-UdR, [125I]iodo-2'--deoxyuridine. 
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lulin [7], as well as virally encoded proteins such as 
vaccinia virus growth factor [8]. 
AR and HB-EGF represent a distinct subset of the EGF 
receptor ligand family in that they possess an extended 
N-terminal sequence which contains a high proportion of 
basic residues, conferring on them the ability to bind to 
heparin with high affinity [5,6] and to localize to the 
nucleus of certain cells [9]. Although AR is equipotent 
with EGF in inducing keratinocyte proliferation [10], it 
differs from EGF in that it exhibits lower affinity for the 
EGF receptor expressed on the surface of A431 cells and it 
cannot synergise with TGFfl to cause anchorage indepen- 
dent growth of NRK cells in soft agar [10]. The reasons for 
these differences have not been evaluated in any detail but 
some studies with keratinocytes [11-14] and human mam- 
mary epithelial cells [15] indicate a role for the interaction 
of the N-terminal heparin-binding domain with heparan 
sulfate proteoglycans (HSPGs). Such an interaction may 
serve to localize the growth factor on the surface of the 
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cell, thereby increasing its effective local concentration r
it may act in a manner similar to that described for basic 
FGF (bFGF) where HSPGs act as low affinity receptors 
and present ligand to the high affinity receptor [16]. 
Studies of the C terminal region of EGF and TGFa 
have revealed the importance of teu  47 or Leu  48 respec- 
tively, for high affinity binding of the ligand to its receptor 
[17-19]. This C terminal leucine residue is conserved in all 
known EGF receptor ligands with the exception of AR 
[10]. The C-terminal region of AR was initially charac- 
terised by microsequencing of the growth factor purified 
from medium conditioned by phorbol ester treated MCF-7 
cells and was found to contain only three residues distal to 
the sixth conserved cysteine residue, terminating with Lys 84 
[10]. Subsequent cloning of the entire cDNA [20] revealed 
AR to be synthesized as a transmembrane pr cursor, simi- 
lar to other members of the EGF receptor ligand family. 
This precursor has a methionine residue downstream of 
Lys 84 in the position corresponding toLeu 47 in EGF. 
As methionine and leucine are structurally similar, we 
investigated whether extending the C terminus of AR by 
six residues utilizing either the natural coding sequence or 
a modified coding sequence incorporating a Met to Leu 
substitution at position 86 (see Table 1) could affect the 
affinity of the growth factor and account for some of the 
observed ifferences in activity between EGF and AR. 
2. Materials and methods 
2.1. Materials 
All chemicals were obtained from Sigma Chemical 
Company, Poole, Dorset, UK, unless otherwise stated. 
Yeast peptone, yeast extract and bacto agar were obtained 
from Difco Laboratories Ltd., West Molesey, Surrey, UK. 
The HiTrap heparin-sepharose column and PepRPC HR5/5 
reverse phase column were obtained from Pharmacia 
Biotech Ltd., St. Albans, Herts., UK. Trifluoroacetic acid 
was from Romil Chemicals Ltd., Loughborough, Leics., 
UK and acetonitrile (HPLC grade) from BDH Laboratory 
Supplies, Merck Ltd., Lutterworth, Leics., UK. All tissue 
culture reagents and plastics were obtained from 
Gibco/Life Technologies Ltd., Paisley, Renfrewshire, 
Scotland, UK. Partially-iron-loaded transferrin was from 
Boehringer Mannheim UK, Lewes, East Sussex, UK and 
5'-[125I]iododeoxyuridine, Hybond C nitrocellulose, hyper- 
film ECL, ECL reagent, anti-rabbit biotinylated Ig, strepta- 
vidin-biotinylated horseradish conjugate and Rainbow 
coloured protein molecular weight markers were obtained 
from Amersham International p c, Little Chalfont, Bucks., 
UK. Biotinylated molecular weight standards were ob- 
tained from Biorad Laboratories Ltd., Hemel Hempstead, 
Herts., UK. Antiphosphotyrosine antibody, PY20, was ob- 
tained from ICN Biomedicals Ltd., Thame, Oxfordshire, 
UK. Recombinant human EGF was obtained from 
Table 1 
C-terminal amino acid residue sequences of EGF, TGFa and the three 
forms of AR 
EGF 41 RCQYRDLKWWELR53 
TGFot 42 RCEHADLLASO 
AR1.84 (wild type) 8°RCGEK84 
AR 1-90 so RCGEKSMKTHS90 
mR 1_90(1eu86 ) 8°RCGEKSLKTHS9° 
The table illustrates the primary sequences of the C-terminal regions of 
EGF, TGFa, AR1.84 , AR1.90 and ARl_90(leu86 ) based on alignment of the 
sixth cysteine residue of each growth factor. Single letter amino acid 
codes are used and the superscript numbers refer to the mature sequence 
residue number. The conserved leucine and the equivalent methionine are 
highlighted in bold. 
Gibco/Life Technologies Ltd,, Paisley, Renfrewshire, 
Scotland, UK, and recombinant human amphiregulin from 
R + D Systems Europe Ltd., Abingdon, Oxfordshire, UK. 
2.2. Methods 
Production of amphiregulin constructs 
Wild type AR (AR1.84) and the C-terminally extended 
forms of the growth factor shown in Table 1 were pro- 
duced as recombinant proteins using a yeast expression 
system utilizing a galactose-inducible y ast alpha-factor 
secretion vector based on the plasmid pWYG9-EGF [21] (a 
gift from Dr. J.J. Clare, Wellcome Research Laboratories, 
Beckenham, Kent, UK). Mature AR coding sequence, 
AR1.84, was obtained by cDNA amplification after reverse 
transcription of whole cell RNA derived from the GP2d 
colorectal carcinoma cell line using nested primers as 
previously described [22]. The internal primer sets were: 
Sense 5'cccctcgagAAAAGA 51° TCAGTCAGAGTI'GAA 
CAG3' 
Antisense 5' 740 GCCACTrGCCACACCCCTITI'CATI" 
cctaggccc3' 
and included 5' XhoI and 3' BamHI restriction sites for 
cloning into an intermediate v ctor as shown in Fig. 1. The 
sense primer also included a cleavage site (Lys-Arg) for 
the yeast KEX2 protease [23] immediately before the first 
residue of mature AR. 
The C-terminally modified AR constructs were gener- 
ated by site directed mutagenesis of the mature AR se- 
quence in M13 phage [24] using the following primers: 
AR I - 90 5!747CGGTGTGGGGAAAAGTCT[  765 ATG] 
AAGACTCATTCITAAggatccgaattcg3' 
t747 765 AR1- 900eus6) 5 CGGTGTGGGGAAAAGTCT[ CTG] 
AACACTCATTCTrAAggatccgaattcg3' 
The sequences of XhoI-BamHI fragments from the inter- 
mediate vectors for wild-type AR and the modified con- 
structs were verified in both directions [20] and then 
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Fig. 1. Generation of recombinanl: yeast alpha-factor secretion vectors for 
wild-type ARl_84 and modified ,~R constructs, ARI_90 and mR1.900eu86). 
An amplified DNA fragment encoding mature AR with 5' XhoI and 3' 
BamHI restriction sites (X,B) was cloned between the XhoI and BamHI 
sites of an intermediate pUC vector, (pUC/TGF/2) which contained the 
yeast gal7 promoter and a-factor prepro leader sequence immediately 5'
of the XhoI site (between Aatl] (A) and XhoI (X) restriction sites), 
generating pUC/AR/1. After sequencing of pUC/AR/1 in both orien- 
tations to confirm the presence of the desired sequence, the AatlI 
(A)-BamHI (B) fragment of pUC/AR/1 was cloned into the AatlI (A) 
and BclI (Bc) sites of pWYG9/EGF to produce pWYG9/AR/1 (step 
2). DNA fragments encoding the modified constructs AR1.90 and 
AR1.90(leu86 ) were generated by eligonueleotide-mediated mutagenesis of 
wild type AR1.84 in M13 and similarly cloned into the intermediate pUC 
vector and pWYG9/EGF as described for wild-type AR1.84. 
cloned into the plasmid pWYG9-EGF for transformation 
into Saccharomyces cerevisiae strain S150-2B 2/x ° (a 
leu2 his3 ura3 trpl) an6 expression as previously de- 
scribed [21]. 
Production and purification of recombinant amphiregulins 
Yeast cells transformed with an appropriate AR expres- 
sion plasmid were grown at 30°C to A600 of 1.0 in 2 1 of 
YP medium containing 1% (w/v) yeast extract, 2% (w/v) 
peptone and 2% (w/v) raffinose and induced to express 
the growth factors by addRion of galactose to 2% (w/v). 
Cultures were grown for a further 36 h and then cen- 
trifuged to remove cells. AR in the medium was precipi- 
tated by addition of solid ammonium sulfate to 60% 
saturation and collected by eentrifugation (27 500 x g, 4°C, 
45 min). The resulting precipitate was resuspended in
phosphate-buffered saline 1co one-tenth the original volume 
for further purification by heparin affinity chromatography. 
ARl.84 , ARI_90 or mR1.90(leuS6 ) were purified by heparin 
affinity chromatography on a 5-ml HiTrap heparin 
sepharose column (Pharmacia) connected to a Pharmacia 
FPLC system. The heparin-bound fraction was eluted with 
either a linear gradient from 0.14-2 M NaCI in PBS or by 
a single step from 0.14 M up to 2 M NaC1 in PBS. 
Fractions were collected, assayed for mitogenic activity 
and peak fractions pooled for further processing or storage 
at - 80°C. 
Heparin affinity purified AR1.84, mR1.9o or mRl_90(leu86 ) 
was further purified using a Pharmacia PepRPC HR5/5 
reverse phase column on a Pharmacia FPLC system. Bound 
protein was eluted using a 0-70% (v/v) linear gradient of 
acetonitrile in aqueous 40 mM TFA over 20 ml. 1-ml 
fractions were collected and lyophilized for subsequent 
analyses. 
SDS-PAGE and Western blotting 
The amounts of AR protein purified after reverse phase 
chromatography were estimated by SDS-polyacrylamide 
gel electrophoresis and Western blotting with ECL detec- 
tion using a procedure similar to that previously described 
[25]. AR protein samples derived after Cls reverse phase 
purification were prepared for SDS-PAGE analysis by 
addition of 5 X concentrated sample buffer to a final 
concentration f 1 X and heated at 95°C for 5 min. The 
samples were analysed in 15% polyacrylamide gels and 
the Western blot was probed with an antibody raised 
against a synthetic peptide comprising the C-terminal 14 
residues of amphiregulin (KCQQEYFGERCGEK) synthe- 
sized on an 8-branched lysine-tree for multiple antigen 
presentation [26]. The antibody was an IgG fraction puri- 
fied from crude rabbit serum by ammonium sulfate pre- 
cipitation and DEAE-ion exchange chromatography. Con- 
trol incubations using antibody preadsorbed with the im- 
munizing peptide were routinely employed to confirm the 
specificity of antibody binding. 
Cell culture 
NR6/HER cells (mouse fibroblasts transfected with the 
human EGF receptor, a gift from Dr. G. Panayotou, Lud- 
wig Institute, London, UK) and A431 vulval epidermoid 
carcinoma cells (obtained from ECACC, Porton Down, 
Salisbury, Wilts., UK) were cultured in Dulbecco's Modi- 
fied Eagle's Medium (DMEM) supplemented with 1 mM 
sodium pyruvate, 1 X non-essential mino acids, 1 mM 
L-glutamine and 50 IU/ml penicillin/50 /zg/ml strepto- 
mycin (all from Life Technologies Ltd., Paisley, Renfrew- 
shire, UK) and 10% heat-inactivated foetal bovine serum 
(DMEM/FBS). NR6/HER cells were cultured in 
DMEM/FBS containing 100 /xg/ml geneticin sulfate 
(G418) as selection for cells containing the EGF receptor 
encoding construct. Cells were grown at 37°C in a humidi- 
fied atmosphere of 5% CO 2 in air. 
25000 Mitogenesis assays 
Mitogenesis assays measuring the ability of EGF or AR 
to stimulate DNA synthesis in confluent and quiescent 
fibroblasts were performed as previously described [27] 
except that NR6/HER fibroblasts were used instead of 
human foreskin fibroblasts. Growth factors were added at 
the concentrations shown in the individual figures. 
Growth inhibition assay 
Growth inhibition assays measuring the ability of EGF 
or AR to inhibit proliferation of A431 vulval epidermoid 
carcinoma cells were performed using a method based on 
that described previously [5]. Cells at a density of 2. 
103/well were incubated with growth factor for 48 h, and 
then pulsed with 0.125 gCi/wel l  5'-[125I]iodo-2-de  
oxyuridine added for a further 5 h. Incorporation of acid- 
stable radioactivity was determined as in the NR6/HER 
mitogenesis assay. 
Receptor tyrosine phosphorylation 
EGF receptor autophosphorylation assays were per- 
formed in 96-well plates using A431 cells at approx. 50% 
confluence. Cells were plated at a density of 1.75.10 4 
cells/well in DMEM/FBS and allowed to adhere 
overnight; after removal of the medium cells were washed 
twice in DMEM, before addition of growth factor diluted 
in 50 gl DMEM. After 10 min incubation at room temper- 
ature, the medium was removed and cells washed once 
with 50 /xl/well prewarmed phosphate-buffered saline. 
The cell layers were then rapidly solubilised in 50/xl/well 
sample buffer (62.5 mM Tris-HC1 (pH 6.8), 2% (w/v) 
SDS, 5% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol, 
0.002% (w/v) bromophenol b ue) containing phosphatase 
inhibitors (1 mM NaF, 1 mM Na3VO4, 70/~M PMSF) by 
heating at 95°C for 5 min. Phosphotyrosine was analysed 
as previously described [25] using biotinylated antiphos- 
photyrosine antibody (PY20). 
3. Results 
Amphiregulin has previously been characterised by its 
ability to inhibit growth of A431 cells in a 2- to 3-day 
proliferation assay [5]. To reduce the time required for 
processing of assays, experiments were performed using 
commercially obtained recombinant EGF and AR to deter- 
mine whether mitogenesis a says utilizing NR6/HER cells 
(murine fibroblasts transfected with the human EGF-recep- 
tor) could be used as a convenient alternative to the A431 
assay. In both assays, AR was found to be less potent han 
EGF: in the NR6/HER assay, AR had an EC50 of 1.5 nM 
and was 50 times less potent han EGF, whereas in the 
A431 assay AR had an IC50 of 90 nM and was approxi- 
mately 300 times less potent han EGF (Fig. 2). Hence the 
former assay was considered to be a suitable system in 
which to measure the activity of AR having the additional 
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Fig. 2. Comparison of the relative potencies of EGF and AR in NR6/HER 
mitogenesis assays and A431 growth inhibition assays. Commercial 
recombinant EGF and AR were tested in a mitogenesis assay using 
NR6/HER cells (a) and in a growth inhibition assay using A431 cells (b) 
as described in Section 2. The figure shows the dose response curve for 
rhEGF ( l l )  and rhAR (O)  in each assay and the error bars represent 
mean + S.D. for duplicate determinations. 
advantages of convenience and sensitivity (cf. the ECso 
and IC50 values for the two assays). 
After expression of AR1_84, AR1.90 and AR1.90(leu86 ) by 
the transformed yeast cells, assay of crude medium for 
mitogenic activity was hindered by non-specific inhibitory 
factors. However, when the growth factors were concen- 
trated by ammonium sulfate precipitation and then were 
assayed, clear differences could be seen in the relative 
mitogenic activity of the three AR preparations with 
mR1.9O(leu86 ) >AR1.90 > AR 1-84 (Fig. 3). 
The three forms of AR were purified by heparin affinity 
chromatography and all eluted between 1.6 and 2 M NaC1; 
similarly, upon C18 reverse-phase chromatography t e three 
forms of AR eluted with approximately 35% acetonitrile 
(data not shown). Thus, it appeared that the C-terminal 
modifications did not significantly affect the behaviour of 
the growth factor in terms of its physicochemical proper- 
ties during purification. It was noted, however, that less 
than 10% of the total mitogenic activity was able to bind 
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Fig. 3. Mitogenic activity of crude AR1.84, ARI_90 and AR1.90(leu86 ). 
Amphiregulin and the C-terminally extended forms of the growth factor 
were expressed by recombinant yeast cells and the growth factor secreted 
into the medium concentrated by ammonium sulfate precipitation. The 
mitogenic activity of this crude preparation was assayed using NR6/HER 
mouse fibroblasts by measurement of uptake of 5'-[12sI]-iodo-2-de  
oxyuridine as described in Section 2. The graph shows mitogenic activity, 
expressed as ng/ml  EGF equivalents for each of the forms of AR. 
to the heparin Sepharose column, suggesting that much of 
the growth factor had lost its N-terminal heparin-binding 
domain as a result of proteolytic degradation. This con- 
tributed to a low overall purification yield. 
The amounts of AR purified after reverse-phase chro- 
matography were estimated by Western blot analysis. The 
blot shown in Fig. 4 demonstrates the standardization f
AR1.84 , ARI_90 and ARl_90(leu86 ) and this formed the basis 
for dilutions which were used in subsequent biological 
assays. For each form of AR, the major species of growth 
factor detected had a molecular weight of approximately 
9.4 kDa consistent with the predicted molecular weight of 
the non-glycosylated mature form of AR. A small amount 
of a higher molecular weight protein was sometimes evi- 
dent in the wild-type AR fraction but its presence was 
variable between preparations. It can also be seen from the 
blot that some degradation of the wild type AR and 
AR1.90(leu86 ) was evident :as both 9.4 and 6 kDa forms of 
the growth factor were detected on the blot. This suggested 
that some of the growth factor had lost its heparin-binding 
domain; however, as the growth factor was purified on the 
basis of its ability to bind to heparin, proteolytic degrada- 
tion may have occurred subsequent to this purification 
step. 
Fig. 5 illustrates the relative potencies of the three 
forms of AR when assayed on NR6/HER cells. Assuming 
equivalent amounts of growth factor as indicated by the 
Western blot, the leucine constuct, AR1.90(leu86), exhibited 
100 times the activity of wild-type AR1.84; this is consis- 
~ ~-21.5kDa 
1 2 3 
AR1-84 
AR1-90 
<---6.5kDa 
~---6.5kDa 
+-- 14.4kl)a 
AR1.90(leu86 ) <----6.5kl)a 
Fig. 4. Western blot of C18 purified fractions of ARl_84, AR1.90 and 
ARl_90(leu86 ). ARl_84 , AR1.90 and ARl.90(leu86 ) were expressed by recom- 
binant yeast cells and purified from the medium by ammonium sulfate 
precipitation, heparin affinity chromatography and Cls reverse phase 
chromatography. The growth factors were analysed by SDS-PAGE and 
Western blotting with a polyclonal antibody directed against he carboxyl 
terminal 14 residues of mature AR as described in Section 2. The blot 
provides an estimate of the molecular weight of the purified ARs and also 
shows standardisation f the three preparations with respect o immuno- 
reactive AR protein concentration. The figure shows (from left to right) 
three increasing doubling dilutions of each growth factor preparation 
which were as indicated. The positions of 21.5 kDa, 14.4 kDa and 6.5 
kDa molecular weight standards are indicated on the right. 
tent with the known difference in activity between EGF 
and EGF which has been C-terminally truncated with the 
loss of Lea 47 [17] or in Lea 47 mutant forms of EGF 
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Fig. 5. Comparison of mitogenic potencies of AR1.84, AR1.90 and 
AR1.90(lcu86 ). The figure illustrates the relative mitogenic activities of the 
three forms of AR after standardization as shown in Fig. 4. The graph 
shows incorporation of 5'-[125I]iodo-2'-deoxyuridine as a measure of 
DNA synthesis by NR6/HER cells in response to equivalent dilutions of 
the growth factors. Results are shown as mean+S.D, for duplicate 
determinations. 
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Fig. 6. Ability of the recombinant forms of All to induce EGF receptor 
tyrosine phosphorylation. Aliquots of purified AR1_84 , AR~.90 and 
AR1.900eu86) were assayed for the ability to induce tyrosine phosphoryla- 
tion of the 170 kDa EGF receptor n A431 carcinoma cells as described 
in Section 2. The Western blot illustrates (from right o left) the amount 
of receptor phosphorylation induced by equivalent amounts ofthe growth 
factors as indicated, when used at three doubling dilutions. The control 
incubation (C), which was performed in the absence of added growth 
factor, measured basal EGF receptor tyrosine phosphorylation and is 
shown on the left. 
[18,19]. Extension of the C-terminus of AR with six 
residues from the predicted coding sequence, AR1.90 also 
enhanced mitogenic activity relative to wild-type activity 
by approximately 10 times. In this construct, methionine 
occupies the position of the conserved leucine; thus the 
structural similarity between leucine and methionine ap- 
pears to be able to substitute, in part, for the leucine and 
confer higher activity on the growth factor. Assay of the 
three forms of AR in the presence of an anti-EGF receptor 
antibody abolished mitogenic activity of them all, indicat- 
ing that they all achieved their effects via the EGF receptor 
(data not shown). 
Binding of ligand to the EGF receptor results in phos- 
phorylation of the receptor on tyrosine residues and subse- 
quent initiation of cellular signalling pathways [28]. To 
determine the relative potencies of the three forms of AR 
in inducing EGF receptor autophosphorylation, they were 
tested on A431 cells. Fig. 6 shows the degree of tyrosine 
phosphorylation f the EGF receptor after incubation with 
equivalent amounts of the three forms of AR. Although 
wild-type AR1.84 was relatively inactive in terms of induc- 
ing DNA synthesis in NR6/HER fibroblasts, it was able to 
induce EGF receptor tyrosine phosphorylation i A431 
cells. The activity of AR1.90 was slightly greater, but the 
leucine construct AR1.90(leu86 ) exhibited a greatly increased 
ability to induce EGF receptor tyrosine phosphorylation 
and was comparable in activity to EGF. 
4. Discussion 
The yeast alpha-factor secretion system has been shown 
to be appropriate for the high level expression of correctly 
folded EGF [21]. In contrast, in the present work much 
lower yields of amphiregulin were obtained, possibly due 
to proteolytic degradation of the N-terminal region which 
is rich in lysine and arginine residues. This proposal is 
consistent with the significant loss of mitogenic activity 
and low yield observed after heparin-affinity purification 
which exploits binding via the N-terminal region of the 
growth factor. Moreover, although the observed size, 9.4 
kDa, of the amphiregulin produced by yeast cells is consis- 
tent with the predicted size of the mature non-glycosylated 
sequence, it has recently been reported that deglycosylated 
AR has a molecular weight of 13.5-14.3 kDa [29]; this is 
probably due to the highly basic nature of the polypeptide 
which causes retardation on SDS-PAGE. The same study 
also identified a 9.4 kDa form of the growth factor which 
had lost 26 residues from its N-terminus. This deletion did 
not affect heparin-binding ability or biological activity 
[29]. Similarly, the existence of multiple forms of HB-EGF 
has also been reported; these display N-terminal hetero- 
geneity but have similar biological activities [30]. To date, 
we have been unable to blot the recombinant amphireg- 
ulins produced by yeast using an antibody raised against 
amino acid residues 8-26 of AR which would be consis- 
tent with truncation of the molecule at the N terminus 
(data not shown). Although differential loss of the N- 
terminus may have accounted for the differences in rela- 
tive activity of the growth factors, this seems unlikely. The 
differences were apparent in crude extracts, which con- 
tained significant amounts of growth factor that could not 
bind to heparin, but were maintained throughout subse- 
quent purification. Furthermore, the 10- to 100-fold in- 
crease in the relative activities of C-terminally extended 
ARs could not be explained easily by inaccuracies inherent 
in determining protein concentration by Western blotting. 
However, we could not confirm this as we were unable to 
purify sufficient material for an accurate protein determi- 
nation. 
It has been shown that progressive truncation of the 
C-terminal tail of EGF has little effect on binding affinity 
and mitogenic potency until Leu 47 is lost [17]. This results 
in a loss in both binding affinity and mitogenic potency by 
more than two orders of magnitude, analogous to the 
difference in ability of AR1.84 and ARl_90(leu86 ) to induce 
DNA synthesis in NR6/HER cells. In view of the well 
documented role of the C-terminal leucine in high affinity 
binding of ligand to the EGF receptor, the greater activity 
of AR1.90(leu86) is perhaps not surprising. Of greater interest 
was the enhanced activity observed by extending the C- 
terminus of AR with six residues from the predicted 
coding sequence (i.e., ARI_90) where methionine replaced 
the conserved leucine residue. Although site-directed mu- 
tagenesis of Leu 47---> Ala in EGF [18,19] (or similarly 
Leu 48 in TGFa, [31]) dramatically reduces receptor bind- 
ing and causes a parallel decrease in mitogenic activity, no 
detailed studies have performed a conservative l u --* met 
mutation. It is noteworthy that an alanine mutation of leu 47 
in EGF caused a 56-fold reduction in binding affinity [18]. 
This is equivalent o a difference in free energies of 
binding of 10 kJ/mol, consistent with the loss of a methy- 
lene and two methyl groups. By comparison, the differ- 
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ences in mitogenic potencies between the C-terminally 
extended ARs containing either leucine or methionine is 
approximately one order of magnitude and would be con- 
sistent with the difference of one methyl group in the side 
chains of these molecules. 
Our results show that extension of the C-terminus of 
AR enhances its activity and this may be of biological 
significance. The AR precursor protein has a methionine 
residue in the position corresponding to the conserved 
leucine, therefore the potential exists in vivo for produc- 
tion of longer forms of AR, such as ARI_90, by alternative 
processing of the AR precursor. Generation of multiple 
forms of AR with differing affinities for the EGF receptor 
would enable modulation of the potency of the growth 
factor and may also affect the range or magnitude of 
signals through the EGF receptor and so elicit pleiotropic 
responses from cells. Moreover, if the membrane-bound 
form of the AR precursor possesses biological activity, as 
has been shown for the TGFa precursor [32,33] then the 
affinity of the AR precursor for the EGF receptor would be 
enhanced by the presence of this methionine residue. In a 
similar context, it is of interest hat a methionine residue 
occurs in the corresponding position (based on alignment 
of cysteine residues) in the heregulins [34]. This group of 
growth factors is structurally related to the EGF receptor 
ligand family and their cellular receptors, HER2 [35] and 
HER4 [36-38], are related to the EGF receptor. The 
importance of Leu 47 for high affinity binding to the EGF 
receptor suggests a similar role for the corresponding 
methionine in binding of the heregulins to their receptors. 
As the C-terminally extended AR1.90 has a methionine in 
the equivalent position, it would be of interest to determine 
whether its receptor specificity has been broadened to 
enable it to interact with not only the EGF receptor but 
also with HER2 or HER4. This would provide another 
opportunity for AR to achieve a range of effects on 
different cell types according to the receptors expressed on 
the cell surface. 
In conclusion, the mitogenic activity of AR has been 
shown to increase by extending the C-terminus to include 
an appropriately positioned methionine or leucine which 
facilitates high affinity binding to the EGF receptor. The 
increased activity of the methionine construct is of particu- 
lar biological significance as the potential exists for a 
higher affinity version of AR to be generated in vivo by 
alternative processing of the AR precursor. It will now be 
of interest to determine whether C-terminally extended 
forms of AR exist in vivo and to determine what factors 
may influence their production. Interaction of the N-termi- 
nal heparin-binding domain with cell surface heparan sul- 
fate provides one way by which the interaction of AR with 
the EGF receptor may be modulated. Differential prote- 
olytic processing of the C-terminus may represent an 
alternative way in which amphiregulin could elicit 
pleiotropic responses in cells. 
Addendum 
Thorne, B.A. and Plowman, G.D. (1994) (Mol. Cell. 
Biol. 14, 1635-1646) cite unpublished observations which 
show that mature 18 kDa AR protein synthesized by 
human keratinocytes or mammary epithelial cells can be 
metabolically labelled with [35S]methionine. As no other 
methionines are found within, or immediately N-terminal, 
to the mature factor, this indicates the existence of natu- 
rally occurring forms of AR with C-termini which extend 
beyond methionine-86. 
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